Maximus Review: What the Prepaid GLP-1 Plans Cost

Maximus is worth comparing if you are comfortable prepaying for compounded tirzepatide and want a published price that does not rise with each dose tier. The important number is the amount due for the whole term. Its advertised $99.99 monthly rate belongs to a twelve-month purchase: $1,199.88 in base charges, with medication sent in two-month shipments. We would settle the renewal and unused-prepayment rules before choosing that discount.

This review covers public offers and policies checked October 26, 2026. We have not enrolled, received medication or tested the service. The pages explain enough to assess the purchase, but do not establish a selected prescription, complete invoice, assigned clinician or dispensing pharmacy. Our recommendation is about those public purchasing terms, not a treatment result.

The monthly price is an allocation of a larger payment

The tirzepatide page offers four plan lengths. Its FAQ says each is billed upfront for the full term, without a separate introductory-month rate or membership fee. Multiplying the published monthly equivalent by the term gives these base charges.

These are base USD calculations, without a promotion applied. They do not establish any additional charges for your purchase or turn the monthly equivalent into a monthly debit.

A lower monthly equivalent therefore requires a larger opening commitment. If you are uncertain about continuing, the two-month offer is the smaller advertised purchase to compare, despite its higher monthly equivalent. Do not choose twelve months solely because $99.99 looks like the next monthly debit. Our six-month cost guide separates cash paid from the portion allocated to a comparison period.

The page also advertises possible split payments. Financing would change how you repay the purchase, not establish that the treatment itself has become a cancelable month-to-month plan. Review the selected payment and care terms together; we did not enter checkout or obtain a financing agreement.

Prepayment and medication delivery follow different schedules

The FAQ says shipments are sent every two months, each containing a two-month supply: one shipment on the shortest term and six on the annual term. Shipping is advertised as free. The published term does not establish a particular vial count, concentration or exact number of usable treatment days for an individual prescription. Confirm those details rather than assuming that twelve months paid means all medication is delivered immediately.

Maximus advertises access to all dose tiers at the flat plan rate, with the prescriber deciding the dose. That is a useful pricing feature to investigate, not permission to choose a higher dose or evidence that every preparation has identical terms. The product is compounded tirzepatide and is not FDA approved. A specific ingredient label, prescribed supply and clinical explanation matter more than an advertised dose tier.

Ask which renewal terms apply to this offer

The tirzepatide FAQ says the plan renews at the same flat rate after the term unless canceled beforehand. The subscription policy on that page allows cancellation through the app or by email before the applicable processing date. It also describes seven days' notice of price or subscription-period changes.

The general Terms of Use contain a separate Subscription Savings Plan section with different wording: monthly installments rather than full-term upfront payment, possible care-driven price changes, and same-duration renewal at the then-current rate with thirty days' notice. Its services paragraph specifically describes a testosterone protocol. We cannot establish that those generic program provisions govern this particular GLP-1 offer, or decide which document would take legal priority.

The practical question is specific: what will be charged now, when does this selected term renew, what will that renewal cost, and how early must you cancel it? Obtain one consistent answer for the plan being purchased. The cancellation guide explains why stopping a future renewal and recovering an earlier payment are different tasks.

The unanswered refund question is the unused prepayment

If treatment is not approved, the product FAQ promises a refund minus the doctor consultation cost. It does not give that consultation amount. Its subscription policy also says shipped medicine is nonrefundable and some laboratory services may require additional payments. Neither statement establishes what happens to the unshipped remainder of a long prepaid purchase if care ends.

The general Savings Plan terms discuss remaining-term payment obligations, a health-related cancellation exception, and different unused-service language when the company ends a program. Those provisions need their applicable scope clarified before being treated as a GLP-1 refund promise. The testosterone-specific treatment guarantee and the separate Maximus Labs refund window are not evidence of a refundable GLP-1 trial.

We would ask for the applicable unused-balance policy before paying for six or twelve months. A low monthly equivalent is less persuasive when the cost of ending early is unclear. Keep the selected offer, cancellation instructions and refund terms together rather than relying only on the price card.

The tirzepatide page excludes three states

The current product and weight-loss FAQs exclude Alabama, Mississippi and Louisiana. Another Maximus company-information page says GLP-1 programs cover all fifty states and Washington, DC. Those statements are inconsistent; the broader description should not be used to override the product's restriction.

Outside the excluded states, browsing the offer still does not establish individual clinical eligibility or verify an assigned clinician's license. Confirm the actual prescription and location before relying on a refill or transferring care. A national brand and a specific treatment's availability are different checks.

Identify the medical practice and pharmacy behind the plan

The legal documents identify Maximus Health, Inc. as the platform operator and distinguish it from independent medical-group practices whose clinicians provide care. They also allow other affiliated practices for some offerings. These general descriptions do not identify the actual practice or professional who would treat a particular patient.

Maximus describes a network of US-based licensed compounding pharmacies, but the reviewed pages do not establish an assigned dispenser or physical compounding facility. Ask for the name and location, then check the relevant current license. The pharmacy verification guide starts with that identity rather than assuming a general quality claim verifies every fill.

Doctor messaging is advertised, but we found no guaranteed response time or fixed GLP-1 laboratory-monitoring schedule in these pages. Clarify who handles medication questions, which tests are required and whether testing or consultations create additional charges. The presence of a separate lab-testing business does not establish that every test is included in the tirzepatide price.

Branded pills and pens are separate offers

Maximus also advertises branded treatment, including Wegovy tablets from $249.99 monthly. That is a different product and price route from the compounded tirzepatide term above. The general weight-loss page has additional branded starting prices, while its comparison text separately says brand-name care starts from $499. We would use the exact product's selected quote rather than treat those displays as one universal branded price.

The menu does not establish which product, strength or pharmacy charge applies to you. An oral listing is not an injectable quote, and a shared ingredient name does not make preparations equivalent. Our oral versus injectable guide explains why the exact product and administration route belong in the comparison.

Our recommendation

Maximus makes the price-versus-term tradeoff visible enough to merit a look. Its flat dose-tier advertising, free shipping and published two-month delivery cadence are concrete features to compare. The first decision is whether you can comfortably commit the actual prepaid total, not whether the annual monthly equivalent looks inexpensive.

We would shortlist it only after confirming the selected billing and renewal terms, the refund treatment of unused unshipped supply, and the treating and dispensing identities. If a short exit or an established unused-balance refund is essential, compare elsewhere first until those answers are clear. We have not established an individual's full treatment bill or a clinical advantage over another service.